File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Expression of P-glycoprotein in hepatocellular carcinoma: A determinant of chemotherapy response

TitleExpression of P-glycoprotein in hepatocellular carcinoma: A determinant of chemotherapy response
Authors
KeywordsHepatocellular carcinoma
Liver
Multidrug resistance
P-Glycoprotein
Issue Date2000
PublisherAmerican Society for Clinical Pathology. The Journal's web site is located at http://www.ajcp.com
Citation
American Journal Of Clinical Pathology, 2000, v. 113 n. 3, p. 355-363 How to Cite?
AbstractTo characterize the P-glycoprotein (Pgp) expression in human hepatocellular carcinoma (HCC), we studied 101 cases of HCC treated with surgical resection without prior treatment. Pgp expression was detected immunohistochemically using 2 monoclonal antibodies (C494, C219) and correlated with pathologic features, survival, and p53 expression. Chemotherapy response was analyzed in a separate group of patients with inoperable HCC treated with systemic chemotherapy. Positive immunostaining was seen in 92% and 80% of the tumors with C494 and C219, respectively; bile canalicular type staining was seen in all positive tumors. Pgp expression was less extensive in the tumors than in the corresponding nontumorous liver tissue. Tumor Pgp expression with either antibody had no association with cellular differentiation, aggressive pathologic features, survival, or p53 overexpression. In patients with inoperable HCC, the chemotherapy response was significantly inversely related to Pgp expression with C494 and C219. Pgp was expressed in human HCC but was patchy and less extensive than in the nontumorous tissue. Response to systemic chemotherapy was inversely related to the level of Pgp expression in patients with inoperable tumors. Pgp expression in tumors not treated with chemotherapy was not associated with a more aggressive tumor phenotype or p53 overexpression and did not influence survival.
Persistent Identifierhttp://hdl.handle.net/10722/148202
ISSN
2015 Impact Factor: 2.278
2015 SCImago Journal Rankings: 1.129
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNg, IOLen_US
dc.contributor.authorLiu, CLen_US
dc.contributor.authorFan, STen_US
dc.contributor.authorNg, Men_US
dc.date.accessioned2012-05-29T06:11:28Z-
dc.date.available2012-05-29T06:11:28Z-
dc.date.issued2000en_US
dc.identifier.citationAmerican Journal Of Clinical Pathology, 2000, v. 113 n. 3, p. 355-363en_US
dc.identifier.issn0002-9173en_US
dc.identifier.urihttp://hdl.handle.net/10722/148202-
dc.description.abstractTo characterize the P-glycoprotein (Pgp) expression in human hepatocellular carcinoma (HCC), we studied 101 cases of HCC treated with surgical resection without prior treatment. Pgp expression was detected immunohistochemically using 2 monoclonal antibodies (C494, C219) and correlated with pathologic features, survival, and p53 expression. Chemotherapy response was analyzed in a separate group of patients with inoperable HCC treated with systemic chemotherapy. Positive immunostaining was seen in 92% and 80% of the tumors with C494 and C219, respectively; bile canalicular type staining was seen in all positive tumors. Pgp expression was less extensive in the tumors than in the corresponding nontumorous liver tissue. Tumor Pgp expression with either antibody had no association with cellular differentiation, aggressive pathologic features, survival, or p53 overexpression. In patients with inoperable HCC, the chemotherapy response was significantly inversely related to Pgp expression with C494 and C219. Pgp was expressed in human HCC but was patchy and less extensive than in the nontumorous tissue. Response to systemic chemotherapy was inversely related to the level of Pgp expression in patients with inoperable tumors. Pgp expression in tumors not treated with chemotherapy was not associated with a more aggressive tumor phenotype or p53 overexpression and did not influence survival.en_US
dc.languageengen_US
dc.publisherAmerican Society for Clinical Pathology. The Journal's web site is located at http://www.ajcp.comen_US
dc.relation.ispartofAmerican Journal of Clinical Pathologyen_US
dc.subjectHepatocellular carcinoma-
dc.subjectLiver-
dc.subjectMultidrug resistance-
dc.subjectP-Glycoprotein-
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntibodies, Monoclonalen_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Therapeutic Useen_US
dc.subject.meshCarcinoma, Hepatocellular - Drug Therapy - Metabolism - Pathologyen_US
dc.subject.meshDrug Resistance, Multipleen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunoenzyme Techniquesen_US
dc.subject.meshLiver Neoplasms - Drug Therapy - Metabolism - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm Recurrence, Localen_US
dc.subject.meshP-Glycoprotein - Metabolismen_US
dc.subject.meshSurvival Analysisen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshTumor Suppressor Protein P53 - Metabolismen_US
dc.titleExpression of P-glycoprotein in hepatocellular carcinoma: A determinant of chemotherapy responseen_US
dc.typeArticleen_US
dc.identifier.emailNg, IOL:iolng@hkucc.hku.hken_US
dc.identifier.emailFan, ST:stfan@hku.hken_US
dc.identifier.authorityNg, IOL=rp00335en_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid10705815en_US
dc.identifier.scopuseid_2-s2.0-0034100195en_US
dc.identifier.hkuros48246-
dc.identifier.hkuros59298-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034100195&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume113en_US
dc.identifier.issue3en_US
dc.identifier.spage355en_US
dc.identifier.epage363en_US
dc.identifier.isiWOS:000085475000005-
dc.publisher.placeUnited Statesen_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats